We identify immune and inflammatory activation as a recurring molecular feature of disease and highlight the contribution of non-neuronal cell populations to the ataxia disease state. These findings extend current understanding of repeat expansion disorders and suggest that immune-related pathways may represent shared components of disease biology across genetically distinct ataxias and potential targets for therapeutic intervention. Continued investigation of these processes in human tissue and experimental models will be important for clarifying their role in disease initiation and progression and for determining whether modulation of immune responses may represent a viable therapeutic strategy in hereditary ataxia.
Tuesday, November 17, 2026
Neuroimmune transcriptional signatures across repeat expansion ataxias in the human brain
Chen, Z., Hicks, A.R., Brenton, J. et al. Neuroimmune transcriptional signatures across repeat expansion ataxias in the human brain. Acta Neuropathol 152, 70 (2026). doi:10.1007/s00401-026-03115-1
Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone
Figueroa, F.; Salinas, L.; Montgomery-Bowie, C.B.; Sellers, R.; Sims, L.; Cox, G.P.; Golove, S.L.; Thai, P.N.; Chiamvimonvat, N.; Cortopassi, G.; et al. Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone. Antioxidants 2026, 15, 1490. doi:10.3390/antiox15111490
DMF partially improved cardiac function in males, increasing stroke volume, enhancing metabolic flexibility, and restoring mitochondrial enzyme activity; however, diastolic dysfunction persisted. OMAV treatment was associated with female-specific electrophysiological abnormalities, including increased arrhythmic burden and reduced J-wave amplitude, with persistent fibrotic remodeling. Both treatments attenuated region-specific cardiomyocyte atrophy in FXNKD males and females. These findings suggest that Nrf2 activation alone is insufficient to reverse FA-associated cardiomyopathy and reveal sex-dependent therapeutic responses. Further investigation of complementary treatment strategies may help address persistent cardiac dysfunction and remodeling in FA.
Monday, November 16, 2026
EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status
Ippazio Cosimo Antonazzo, Paolo Angelo Cortesi, Lorenzo G. Mantovani, Richard Lawson, Leila Khader, Claudia Oliviero, Laura Santoni, Antonio Cittadini, Gabriella Paparella, Francesco Saccà, EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status, Value in Health, Volume 28, Issue 12, Supplement 1, 2025, Pages S203-S204, ISSN 1098-3015, doi:10.1016/j.jval.2025.09.879.
Loss of ambulation increases FA patient management costs from both NHS and societal perspectives.
Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation
Zhou, J., Ma, X., Jiang, B. et al. Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation. Nat Commun 17, 11202 (2026). doi:10.1038/s41467-026-77760-1
Aberrant activation of the STING signaling pathway is involved with aging-related inflammation, yet no STING-targeting therapeutics are clinically approved. Here, we identify Omaveloxolone, an FDA-approved drug for Friedreich’s ataxia, as a potent STING degrader (DC50 = 118 nM, Dmax = 98.6%) via high-throughput screening.
This study implicates Omaveloxolone as a molecular crowbar-like STING degrader and provides a mechanistic framework for targeting STING via conformational perturbation.
Larimar Narrows Q3 Loss; Completes BLA Submission For Nomlabofusp In Friedreich's Ataxia
Published: 11/16/2026. Larimar completed its rolling BLA submission to the U.S. Food and Drug Administration (FDA), seeking accelerated approval of nomlabofusp for adults and pediatric patients with Friedreich's ataxia. The application uses frataxin (FXN) as a potential novel surrogate endpoint.
BLA submission acceptance is expected in early 2027. An open-label study safety update is anticipated in the first quarter of 2027, followed by a potential U.S. approval in mid-2027, subject to FDA review.
If approved, Larimar is targeting a U.S. commercial launch in the third quarter of 2027. The company also expects to obtain and monetize a Rare Pediatric Disease Priority Review Voucher in mid-2027, if nomlabofusp receives approval.
Sunday, November 15, 2026
FXN protomutations are the source of pathogenic expanded GAA alleles in Friedreich ataxia and explain its unequal population distribution
Devore MC, Lam C, Xiao E, Devore J, McCain KRC, Wiley G, Park CC, Lynch DR, Bidichandani SI. FXN protomutations are the source of pathogenic expanded GAA alleles in Friedreich ataxia and explain its unequal population distribution. Hum Mol Genet. 2026 Jun 9;35(11):ddag046. doi: 10.1093/hmg/ddag046. PMID: 42262226; PMCID: PMC13248553.
These data indicate that FXN protomutations serve as a reservoir for the generation of premutation and E alleles, and for millennia have sustained the geographically-defined population distribution of FRDA.
Integration of Evolutionary Analysis With RFdiffusion for De Novo Design of Aggregation-Resistant Frataxin
Kırboğa KK, Küçüksille EU. Integration of Evolutionary Analysis With RFdiffusion for De Novo Design of Aggregation-Resistant Frataxin. Proteins. 2026 Jun;94(6):1225-1244. doi: 10.1002/prot.70114. Epub 2026 Jan 21. PMID: 41563298.
This work establishes a generalizable framework for therapeutic protein engineering where backbone redesign enables conformational ensemble modulation beyond the limitations of sequence optimization alone.
Nerve ultrasound as a biomarker in Friedreich’s ataxia
Giuseppe Di Pietro, Ettore Cioffi, Pietro Falco, Caterina Leone, Giulia Di Stefano, Eleonora Galosi, Gianfranco De Stefano, Valentina Martinez, Stefano Perotti, Carlo Casali, Andrea Truini,, PO 286 Nerve ultrasound as a biomarker in Friedreich’s ataxia, Clinical Neurophysiology, Volume 185, 2026, 2111295, ISSN 1388-2457, doi:10.1016/j.clinph.2025.2111295.
All patients exhibited severe sensory axonal neuropathy. HRUS showed significant CSA enlargement in the median and ulnar nerves at the axilla and upper arm. The number of affected nerve sites correlated directly with disability scores (SARA, FARS, mFARS, ADL 0-36, INCAT) and inversely with IADL.
Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics
Giusy Russomanno, Karolina Kwiatkowska, Ian M. Copple, Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics, Redox Biology, Volume 92, 2026, 104128, ISSN 2213-2317, doi:10.1016/j.redox.2026.104128.

Hormonal status, age, and tissue-specific receptor distribution further modulate these effects, suggesting that therapeutic responses to NRF2 activators are inherently sex-dependent. Pharmacokinetic and pharmacodynamic differences, including CYP3A-mediated metabolism and body composition, may additionally influence systemic exposure and safety profiles. Despite clinical use of NRF2 activators such as dimethyl fumarate and omaveloxolone, sex-stratified data on efficacy, dosing, and safety are scarce. This knowledge gap underscores the need for systematic evaluation of sex, hormonal milieu, and age in pharmacokinetic, pharmacodynamic, and clinical studies to ensure treatments are safe, effective, and equitable. Integrating these variables into research and clinical practice will optimise therapeutic benefits and minimise adverse events by accounting for patient-specific biology.

Nonclinical efficacy and safety evaluation of SGT-212, a novel investigational AAV FXN gene therapy for the treatment of Friedreich’s ataxia
Nonclinical efficacy and safety evaluation of SGT-212, a novel investigational AAV FXN gene therapy for the treatment of Friedreich’s ataxia, Brandon YH Chan, Jun Lee, Jamie Marshall, Matthew Harmelink, Gourav Roy Choudhury, Heather Born, Juliette Hordeaux, James M Wilson, Jessie Hanrahan, Gabriel Brooks, Nicolas Christoforou. Solid Biosciences, Charlestown, USA; University of Pennsylvania, Philadelphia, USA. doi:10.1016/j.nmd.2026.106596
These positive nonclinical data supported initiation of the Phase 1b FALCON trial (NCT07180355), an actively enrolling first-in-human study of SGT-212.
Genetic prevalence of repeat expansion and other rare neurological disorders in the Quebec population
De Mori A, Labrecque M, Triassi V, Audet S, Pelletier J, Lai A, La Piana R, Duquette A, Bhérer C and Tetreault M (2026) Genetic prevalence of repeat expansion and other rare neurological disorders in the Quebec population. Front. Genet. 17:1964104. doi: 10.3389/fgene.2026.1964104
Among the diseases expected to be enriched in the CaG cohort given their established association with the French-Canadian founder effect, FXN and DMPK variants were identified at elevated frequencies, as anticipated. The high CF of FXN variants is consistent with the autosomal recessive nature of FRDA, in which carriers are unaffected and therefore not excluded during recruitment of CaG participants. The recent approval of omaveloxolone as a therapy for FRDA further increases the clinical value of identifying expansion carriers early in the Quebec population
![]() |
Cells heal themselves: gene-edited hematopoietic stem cells restore frataxin deficiency in multiple organs
Lucy R. Osborne. Cells heal themselves: gene-edited hematopoietic stem cells restore frataxin deficiency in multiple organs. J Clin Invest. 2026;136(20):e211630. doi:10.1172/JCI211630.
There is undoubtedly a lot of work to be done optimizing the editing efficiency of the repeat expansion, cell engraftment, and the timing of delivery, but the results reported by Sivakumar et al. are very encouraging and demonstrate that even with relatively limited editing and chimerism, there were concrete improvements in neurological, pancreatic, and cardiac function in the humanized mouse model of FRDA.
Recent developments in Friedreich's ataxia: a state-of-the-art review
Chapman LR, Mortiboys H, Shaw PJ. Recent developments in Friedreich's ataxia: a state-of-the-art review. Brain Commun. 2026 Apr 20;8(3):fcag143. doi: 10.1093/braincomms/fcag143. PMID: 42158846; PMCID: PMC13180647.
We have conducted a critical review of all the studies published between 1999 and December 2024. The free text search terms were ((Friedreich's Ataxia) OR (FRDA) OR (FRDA) OR (inherited ataxias)) AND ((recent developments) OR (new developments) OR (new treatments) OR (phenotype)).
Wednesday, November 11, 2026
Metabolic dysfunction in Friedreich ataxia
David Lynch, Clementina Mesaros, Elizabeth Mercado Ayon, Yi Na Dong; Metabolic dysfunction in Friedreich ataxia. Open Biol. 1 November 2026; 16 (11): 260221. doi:10.1098/rsob.260221
This review traces that logic from the cell to the organ to the whole body. The same map defines a compact panel of blood-based biomarkers, anchored on frataxin protein itself and extended by chain-resolved ceramides and by the succinate : fumarate, BHB : acetoacetate, NAD+ : NADH and GSH : GSSG ratios. It also nominates targets that do not require restoration of frataxin, including NRF2 activation, ferroptosis inhibition, NAD+ and sirtuin repletion, PPARgamma agonism, anaplerosis and ketone-based therapy. Reframing FRDA as a disorder of fuel logistics, rather than of fuel combustion alone, explains why a globally reduced protein produces a selective yet multisystem disease.
Monday, November 9, 2026
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
BALA CYNWYD, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. today announced completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich’s ataxia (FA). Completion of the submission follows previously disclosed FDA feedback on key elements of the BLA and represents a significant milestone for Larimar. Larimar is currently enrolling patients in FORWARD-FA, its global confirmatory Phase 3 study, a double-blind, placebo-controlled study that will evaluate daily subcutaneous use of nomlabofusp over 18 months in ambulatory participants ages 2 to 40 who are new to the drug. Approximately two thirds of the participants will be under the age of 21.
Submission Highlights:
Data Package Supporting Submission and Review: FDA reviewed OL study data submitted in a briefing package and confirmed in minutes from the multidisciplinary Type B pre-BLA meeting that the existing data package appears capable of supporting submission and review of a BLA seeking accelerated approval of nomlabofusp as a treatment for patients with FA. Approval will be a matter of review.
FXN as a Potential Surrogate Endpoint: In those previously disclosed interactions, FDA reaffirmed its willingness to consider FXN as a novel surrogate endpoint and indicated that Larimar’s exposure-response analysis linking nomlabofusp exposure to clinical outcomes is the type of analysis that could support the BLA submission.
Additional Biological Evidence: FDA previously noted that prospectively collected exploratory gene expression and lipid pharmacodynamic markers data may help further characterize the biological activity of nomlabofusp beyond tissue FXN concentrations.
Potential Upcoming Milestones
BLA Submission Acceptance: Early 2027
Open Label Study Safety Update: Q1 2027
U.S. Approval: Mid-2027
Obtaining & Monetizing the Rare Pediatric Disease Priority Review Voucher: Mid-2027, if approved
U.S. Launch: Targeting Q3 2027 launch, if approved.
Overcoming the challenges of rare disease clinical research
Tunis, S., Caro, J., Abraham, P. et al. Overcoming the challenges of rare disease clinical research. Orphanet J Rare Dis (2026). doi:10.1186/s13023-026-04668-w
This review focuses primarily on clinical development and regulatory evidence-generation strategies for rare diseases, while also highlighting how residual uncertainty may affect subsequent health technology assessment, reimbursement, and access decisions. We provide examples of drug approval processes and outline various potential strategies for clinical development of rare disease treatments, highlighting the strengths of each technique and discussing the opportunities to enhance clinical research.
Nationwide Assessment of Friedreich’s Ataxia in Sweden: Epidemiology and Patient-Reported Outcomes
Dobloug S, Jennions E, Svenning P ... Nationwide Assessment of Friedreich’s Ataxia in Sweden: Epidemiology and Patient-Reported Outcomes
Parkinsonism & Related Disorders, 152. DOI: 10.1016/j.parkreldis.2026.108448
Friedreich’s ataxia (FRDA) is considered the most common hereditary ataxia globally, yet marked variation in prevalence has been reported. FRDA prevalence is considered lower in Northern European countries than in other populations, but contemporary epidemiological data are limited. The aim of this study is to investigate the national prevalence of FRDA in Sweden and to characterize demographic patterns, clinical severity, and quality of life within the Swedish FRDA population.
Guide to Cerebellar Ataxic Disorders
Francisco Javier Arpa Gutiérrez, Francisco Javier Rodríguez de Rivera, Irene Sanz Gallego, Susana Chajma Izquierdo, Guide to Cerebellar Ataxic Disorders,
Neurology Perspectives, 2026, 100242, ISSN 2667-0496, doi:10.1016/j.neurop.2026.100242.
We refer to the main epidemiological data on cerebellar ataxias, preferably focused on Spain, and describe their clinical and paraclinical evaluation. We develop a characteristic pathway: the presentation in the patient of a progressive or stable (non-progressive) cerebellar ataxia, which may have a hereditary origin, be a primary acquired ataxia, or be a secondary ataxia, and we address its diagnosis and management.
DNA double-strand break repair deficiency in Friedreich’s Ataxia: Radioprotective role of Zoledronic Acid and Pravastatin
Rafka Salim Challita, Dana Tohme, Leen Abou Najem, Hussein Khram, Walaa Chebli, Gilbert Antaki, Charbel Feghaly, Hanine Bou Hadir, Rana El-Hassan, Wassim Abou-Kheir, Larry Bodgi, 2199 DNA double-strand break repair deficiency in Friedreich’s Ataxia: Radioprotective role of Zoledronic Acid and Pravastatin, Radiotherapy and Oncology, Volume 218, Supplement 1, 2026, Pages S2619-S2620, ISSN 0167-8140,
doi:10.1016/S0167-8140(26)03991-5.
Conference abstract
Adjuvia Therapeutics Initiates Phase 1 Clinical Trial of ATI-105 for Friedreich’s Ataxia
Oct 28, 2026. SAN FRANCISCO--(BUSINESS WIRE)--Adjuvia Therapeutics, a biotechnology company developing novel therapeutics to treat mitochondrial dysfunction and disease, today announced that the first participant has been dosed in its Phase 1 clinical trial of ATI-105, its lead investigational therapeutic candidate for Friedreich’s ataxia (FA). The milestone follows the U.S. Food and Drug Administration's (FDA) acceptance of the company's Investigational New Drug (IND) application in September.Adjuvia plans to advance ATI-105 into Phase 1/2 studies in FA in 2027, with a focus on addressing lethal cardiomyopathy, followed by expansions into Leigh syndrome and primary mitochondrial diseases (PMD) in 2028.
La FDA investiga formalmente el riesgo de cáncer de las dos terapias génicas de Novartis para la atrofia muscular espinal
Published 08 November 2026. El regulador amplía el escrutinio a Itvisma pese a que no se han notificado casos; tres programas independientes basados en AAV están vinculados a la activación de oncogenes del desarrollo mediante un elemento promotor CAG común.
La Administración de Alimentos y Medicamentos de Estados Unidos (FDA) anunció formalmente el jueves que investiga un riesgo grave de malignidad asociado a las dos terapias génicas aprobadas de Novartis para la atrofia muscular espinal —Zolgensma e Itvisma— después de que el análisis molecular de tejido tumoral de pacientes tratados con Zolgensma confirmara un mecanismo causal concreto: el ADN del vector viral de la terapia se integra en el genoma cerca de un gen conocido por impulsar el cáncer, denominado GLI1, y lo activa.
La medida de la FDA, publicada el 6 de noviembre por su Centro de Evaluación e Investigación de Productos Biológicos (CBER), supone la primera ocasión en que un regulador estadounidense caracteriza formalmente una terapia génica comercial basada en AAV como causante de oncogénesis insercional en seres humanos. El riesgo pasa así de ser "teórico" —la formulación que todavía figura en la ficha técnica de Zolgensma— a estar confirmado y sujeto a una investigación activa.
FDA Formally Investigates Cancer Risk From Both Novartis SMA Gene Therapies After GLI1 Oncogene Activation Confirmed in Zolgensma Cases
Published: Nov 07 2026, Regulator extends scrutiny to Itvisma despite zero reported cases; three independent AAV programs now linked to developmental oncogene activation via shared CAG promoter element.
The U.S. Food and Drug Administration formally announced Thursday that it is investigating a serious risk of malignancy linked to both of Novartis's approved gene therapies for spinal muscular atrophy — Zolgensma and Itvisma — after molecular analysis of tumor tissue in Zolgensma patients confirmed a specific causal mechanism: the therapy's viral vector DNA integrating into the genome near a known cancer-driving gene called GLI1 and switching it on.
The FDA's action, published November 6 by its Center for Biologics Evaluation and Research (CBER), marks the first time a U.S. regulator has formally characterized a commercial AAV gene therapy as having caused insertional oncogenesis in humans — moving the risk from "theoretical," the language still on Zolgensma's product label, to confirmed and under active investigation.
In vivo frataxin expression of a triplex purified minicircle
Mozafari, N., Milagres, S., Cuellar, R. et al. In vivo frataxin expression of a triplex purified minicircle. Gene Ther (2026). doi:10.1038/s41434-026-00653-x
Minicircles (MCs) are non-viral DNA vectors offering improved safety and efficiency over conventional plasmids. We used a novel method to purify MCs using biotin-conjugated triplex-forming and strand-invading oligonucleotides (ONs). A 21 bp H-DNA-forming sequence was incorporated into the plasmids to enhance binding specificity of the ONs. The ON-plasmid complexes were removed using streptavidin magnetic beads. This approach yielded highly purified MCs.
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
CHARLESTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
SGT-212 for Friedreich's ataxia (FA)
Five participants have been dosed with SGT-212 in the Phase 1b FALCON clinical trial, with no treatment-related serious adverse events observed as of November 3, 2026.
Participant screening and enrollment remain ongoing, and Solid expects to report initial data in the first quarter of 2027, subject to participant enrollment.
In October, SGT-212 received Orphan designation for the treatment of Friedreich's ataxia from the European Commission, acting upon the positive opinion of the European Medicines Agency's Committee for Orphan Medicinal Products.
Dysregulation of iron metabolism and mitochondrial function across tissues in the FXNI151F mouse model of Friedreich Ataxia: from cellular to systemic alterations
Pazos Gil, M. (2026). Dysregulation of iron metabolism and mitochondrial function across tissues in the FXNI151F mouse model of Friedreich Ataxia: from cellular to systemic alterations. Universitat de Lleida. https://hdl.handle.net/10803/698734
This thesis explores the effects of frataxin deficiency across different tissues and stages of the disease using the FXNI151F mouse model, which exhibits partial systemic frataxin deficiency and reproduces neurological defects observed in patients.
Geometric brain signatures for characterising hereditary ataxia and predicting functional brain organisation: a retrospective multicohort study
Zuitian Tao, Gilles Naeije, Fuad Noman, Thiago J R Rezende, Marcondes C França, Alex Fornito, Ian H Harding, Nellie Georgiou-Karistianis, Trang Cao, Susmita Saha, Nellie Georgiou-Karistianis, Louise A Corben, Eric F Lock, Helena Bujalka, Isaac Adanyeguh, Manuela Corti, Daniel Chung, Martin Delatycki, Imis Dogan, Jennifer Farmer, Marcondes França, Anthony S Gabay, William Gaetz, Ian H Harding, Pierre-Gilles Henry, James Joers, Christophe Lenglet, Michelle A Lax, Jiakun Li, David Lynch, Thomas Mareci, Alberto R M Martinez, Massimo Pandolfo, Marina Papoutsi, Myriam Rai, Kathrin Reetz, Thiago J R Rezende, Timothy P Roberts, Sandro Romanzetti, David A Rudko, Susmita Saha, Jörg B Schulz, S H Subramony, Veena G Supramaniam, Geometric brain signatures for characterising hereditary ataxia and predicting functional brain organisation: a retrospective multicohort study, The Lancet Medical Imaging & Theranostics, Volume 1, Issue 2, 2026, 100016, ISSN 3117-4523, doi:10.1016/j.lanmit.2026.100016.
The study analysed MRI scans from over 500 participants across three independent cohorts, including people with Friedreich ataxia, spinocerebellar ataxia types 1 and 3, and healthy participants. The model analysed brain scans using 200 geometric features that captured patterns of brain structure and activity across the whole brain.
The exploratory geometry-driven deep learning approach used in this study proposes to describe brain changes across multiple scales by integrating structural and functional information and predicts brain function when fMRI data are unavailable. Thus, geometric brain signatures might support biomarker development for HCA subtype differentiation and disease progression tracking in larger prospective studies.
Neurocrine Biosciences Q3 Earnings Call Highlights
Nov 3, 2026. NBIB-’223, a Friedreich’s ataxia gene therapy being developed with Voyager Therapeutics, is expected to enter phase I in the coming months, with initial patient-level data anticipated in 2027.
Graviton BioScience Announces FDA Fast Track Designation for GV101 for the Treatment of Friedreich's Ataxia
NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Graviton BioScience today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to GV101, the Company's clinical-stage, potent and selective oral Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, for the treatment of Friedreich's ataxia (FA).
GV101 is one of Graviton's proprietary, investigational oral selective ROCK2 inhibitors. ROCK2 inhibition is a novel mechanism for FA therapy that targets the root genetic cause of the disease by increasing both frataxin transcription and translation. This genetic restoration alleviates mitochondrial dysfunction and cellular stress in cardiovascular and neurological tissues. Furthermore, ROCK2 inhibition has been shown to offer neuroprotection, promoting axonal regeneration and increasing neuronal survival. Promising preclinical studies have demonstrated that GV101 increases frataxin mRNA and protein levels, providing a potentially disease-modifying therapeutic approach to Friedreich's ataxia.
Stimulated protein degradation to promote mitochondrial function and neuronal survival
Srividya Chandrasekhar et al. ,Stimulated protein degradation to promote mitochondrial function and neuronal survival. Science394,eaed2525(2026).DOI:10.1126/science.aed2525
We show that activators of the reductive stress response E3 CUL2FEM1B boost degradation of multiple physiological substrates to improve mitochondrial import and electron transport chain assembly. In this manner, CUL2FEM1B agonists preserve mitochondrial function and neuronal survival in models of neurodegenerative COX deficiency syndrome and Friedreich’s ataxia.
Researchers have now developed a strategy called stimulated protein degradation (SPD), which activates the cell's natural protein-clearance system to accelerate the breakdown of multiple proteins.The compound also demonstrated beneficial effects in cellular models of other mitochondrial disorders, including Friedreich's ataxia, an inherited condition associated with a deficiency of the protein frataxin.
In the experimental model, BD2 produced effects comparable to those observed with optimal concentrations of omaveloxolone, an approved treatment for Friedreich's ataxia. However, the approach did not correct every mitochondrial defect tested.
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
Press Release Date 11-02-2026. NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc.
LX2006 Clinical Data Update
New phase I/II interim clinical data continue to show sustained or deepening improvements across cardiac and neurologic measures of FA, including statistically significant improvement in mean mFARS scores for LX2006-treated participants compared to a propensity-matched control cohort from the UNIFAI natural history study.
Among all participants with 24 months of follow-up (n=11), treatment with LX2006 resulted in a mean improvement of 2.13 points per year, or 4.26 points over two years, on the mFARS scale compared to propensity-matched control.
Among a subset of participants with 36 months of follow-up (n=7), treatment with LX2006 resulted in further improvement, with a mean change of over 4 points relative to baseline
Both neurologic and cardiac measures, including mFARS, left ventricular mass index (LVMI) and troponin, demonstrate durable benefit and continued improvement over time.
Subscribe to:
Posts (Atom)

